EQS-News: Redcare Pharmacy’s CardLink solution for e-Rx redemption extended by gematik, enabling a smooth transition to the next generation technology.
|
EQS-News: Redcare Pharmacy N.V.
/ Key word(s): Regulatory Approval
Redcare Pharmacy’s CardLink solution for e-Rx redemption extended by gematik, enabling a smooth transition to the next generation technology. Sevenum, the Netherlands, 15 July 2025. Today Redcare Pharmacy was notified by its technology partner eHealth Experts that an extension until 31 January 2027 for its CardLink product license has been received. Redcare’s CardLink solution has been available in the Shop Apotheke app since May 2024, allowing patients in Germany to redeem their prescriptions digitally. With the extension of its CardLink solution, Redcare’s access to the German e-prescription market continues and remains secured during the transition to the new Proof of Patient Presence (PoPP) infrastructure. This next generation technology (PoPP) will continue to support electronic health card (eGK) redemption without PIN. Additionally, PoPP will provide an even higher standard of security and could offer more authentication options, such as biometric verification via Face ID or fingerprint. The new functionalities are expected to become available in late 2026. Redcare Pharmacy’s CEO, Olaf Heinrich comments: “The extension of CardLink is a logical step for a smooth transition to the PoPP infrastructure. We are looking forward to the introduction of this new national standard, which will make prescription redemption even more convenient for patients.”
Investor Relations Contact: Monica Ambrosi (Associate Director, Investor Relations) investors@redcare-pharmacy.com
Press Contact: Sven Schirmer (Director, Corporate Communications)
About Redcare Pharmacy Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven. As the one-stop pharmacy of the future, Redcare Pharmacy offers over 13 million active customers a wide range of more than 250,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management. Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.
15.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2169990 |
| End of News | EQS News Service |
|
|
2169990 15.07.2025 CET/CEST
Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL.
| Die wichtigsten Finanzdaten auf einen Blick | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Umsatzerlöse1 | 968,06 | 1.060,32 | 1.204,35 | 1.798,76 | 2.370,58 | 2.940,90 | 3.353,00 | |
| EBITDA1,2 | 15,20 | -38,73 | -29,66 | 39,99 | 29,23 | 47,40 | 77,00 | |
| EBITDA-Marge3 | 1,57 | -3,65 | -2,46 | 2,22 | 1,23 | 1,61 | 2,30 | |
| EBIT1,4 | -0,87 | -65,70 | -69,17 | -17,30 | -38,99 | -28,50 | 9,00 | |
| EBIT-Marge5 | -0,09 | -6,20 | -5,74 | -0,96 | -1,65 | -0,97 | 0,27 | |
| Jahresüberschuss1 | -16,77 | -74,19 | -77,65 | -11,61 | -46,36 | -39,40 | -15,00 | |
| Netto-Marge6 | -1,73 | -7,00 | -6,45 | -0,65 | -1,96 | -1,34 | -0,45 | |
| Cashflow1,7 | 17,80 | 11,64 | -29,11 | 61,46 | 22,13 | 31,00 | 39,00 | |
| Ergebnis je Aktie8 | -1,17 | -4,15 | -4,32 | -0,73 | -2,27 | -1,87 | -0,73 | |
| Dividende8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Forvis Mazars
Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.
| INVESTOR-INFORMATIONEN | ||||||
| ©boersengefluester.de | ||||||
| Redcare Pharmacy | ||||||
| WKN | ISIN | Rechtsform | Börsenwert | IPO | Einschätzung | Plus Code |
| A2AR94 | NL0012044747 | N.V. | 770,87 Mio € | 13.10.2016 | Halten | 9F3893WC+F5 |
| KGV 2027e | KGV 10Y-Ø | BGFL-Ratio | Shiller-KGV | KBV | KCV | KUV |
| 22,70 | 0,00 | 0,00 | -19,99 | 1,68 | 24,87 | 0,26 |
|
Dividende '2023 in € |
Dividende '2024 in € |
Dividende '2025e in € |
Div.-Rendite '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Hauptversammlung | Q1-Zahlen | Q2-Zahlen | Q3-Zahlen | Bilanz-PK |
| 15.04.2026 | 06.05.2026 | 29.07.2026 | 29.10.2026 | 04.03.2026 |
| Abstand 60-Tage-Linie | Abstand 200-Tage-Linie | Performance YtD | Kursveränderung 52 Wochen | IPO |
| -30,82% | -48,41% | -43,11% | -69,64% | +33,79% |
Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.
Kontakt
